Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jul;2(3):e23.
doi: 10.2349/biij.2.3.e23. Epub 2006 Jul 1.

Radioimmunotherapy: a brief overview

Dce Ng  1
Affiliations

Radioimmunotherapy: a brief overview

Dce Ng. Biomed Imaging Interv J. 2006 Jul.

Abstract

With the advent of biotechnological advances and knowledge of molecular and cellular biology, radioimmunotherapy (RIT) has become a highly promising oncologic therapeutic modality with established clinically efficacy, particularly in non-Hodgkin's lymphomas. This paper provides a short survey of the basic science of RIT and the various monoclonal antibodies and radionuclides used. A brief review of the published literature on the clinical applications of radioimmunotherapy, particularly in non-Hodgkin's lymphoma, is provided. New research data indicate many potential areas of development of this modality, including haematological and solid-organ radioimmunotherapy as well as new radionuclidic approaches and clinical protocols.

Keywords: Monoclonal antibodies; ibritumomab tiuxetan; oncology; tositumomab.

PubMed Disclaimer

References

    1. Kroger L A, DeNardo G L, Gumerlock P H, et al. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low-dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biotherapy & Radiopharmaceuticals. 2001;16(3):213–25. - PubMed
    1. Bennett J M, Kaminski M S, Leonard J P, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukaemia in patients with non-Hodgkin’s lymphoma treated with tositumomab and I-131 tositumomab. Blood. 2005;105:4576–82. - PubMed
    1. Turner J H, Martindale A A, Boucek J, et al. I-131-anti-CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin’s lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radio-labelled in a hospital. Cancer Biotherapy & Radiopharmaceuticals. 2003;18:513–24. - PubMed
    1. Witzig T E, White C A, Wiseman G, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3793–3803. - PubMed
    1. Witzig T E, Flinn I W, Gordon L I, et al. Randomised controlled trial of Y-90 labelled ibritumomab tuixetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–2463. - PubMed

LinkOut - more resources